Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.

Source:http://linkedlifedata.com/resource/pubmed/id/19898504

Download in:

View as

General Info

PMID
19898504